A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Adult Subjects With Generalized Pustular Psoriasis
Phase: PHASE3
Conditions: Generalized Pustular Psoriasis
Sponsor: Vanda Pharmaceuticals

Long-Term Safety and Efficacy of Imsidolimab in Subjects with GPP 
 
 
Clinical Study Protocol 
Protocol ANB019-302  
 
 
 
 
 
 
 
19 August 2022 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 
 
1 
 
 
 
 
IMSIDOLIMAB 
A Phase 3, Long-Term Extension Study to Evaluate 
the Safety and Efficacy of Imsidolimab (ANB019) in 
the Treatment of Adult Subjects with Generalized 
Pustular Psoriasis 
 
Protocol Number: ANB019-302 
Phase: III 
Investigational New Drug (IND) Number: 136145 
European Clinical Trials Database (EudraCT) Number: 2021-001448-90 
NCT Number: NCT05366855 
 
 
 
 
 
Sponsor Name: AnaptysBio, Inc. 
Sponsor Address: 10770 Wateridge Circle, Suite 210 
San Diego, CA 92121, United States 
 
 
 
 
 
 
 
Clinical Study Protocol 
19 August 2022 

Long-Term Safety and Efficacy of Imsidolimab in Subjects with GPP 
 
 
Clinical Study Protocol 
Protocol ANB019-302  
 
 
 
 
 
 
 
19 August 2022 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 
 
2 
1.1 
SYNOPSIS 
 
 
 
 
Title: 
A Phase 3, Long-Term Extension Study to Evaluate the Safety and Efficacy of 
Imsidolimab (ANB019) in the Treatment of Adult Subjects with Generalized 
Pustular Psoriasis 
Short Title: 
Long-Term Safety and Efficacy of Imsidolimab in Subjects with Generalized 
Pustular Psoriasis 
Study 
Description: 
This is a Phase 3, long-term extension study to evaluate the safety and efficacy 
of imsidolimab in adult subjects with generalized pustular psoriasis (GPP). 
This study will also evaluate the pharmacokinetics (PK) of imsidolimab and 
explore the immunogenicity of imsidolimab in subjects with GPP. 
To be eligible for this study, subjects must have participated in the preceding 
placebo-controlled Phase 3 study ANB019-301. In addition, subjects will be 
allowed to enter this long-term extension study if one of the following criteria 
is met: 
• If they completed at least the Week 1 visit of the ANB019-301 study 
without the use of rescue/prohibited medication for GPP and needed rescue 
medication starting at Week 1 or later during the ANB019-301 study; or 
• If they completed the Week 4 visit of the ANB019-301 study, and did not 
need or use rescue/prohibited medication for GPP during their entire 
participation in the ANB019-301 study. 
The Day 1 visit of this study should ideally occur on the same day as the final 
study visit of the ANB019-301 study, in which case, subjects will enter this 
study directly after all assessments of the final ANB019-301 study visit are 
completed. Assessments that are common to both studies will be performed 
only once if the visits are on the same day. If scheduled on two separate days, 
the Day 1 visit of this study should occur no later than 1 week after 
completing the final study visit of the ANB019-301 study. No screening visit 
is required for this study. 
During the treatment period, subjects will receive the treatment based on their 
status upon entry into this study (additional details of treatment administration 
are provided in Table 2): 
• Responders: subjects who completed the Week 4 visit of the ANB019-301 
study and have a Generalized Pustular Psoriasis Physician’s Global 
Assessment (GPPPGA) score of 0 (clear) or 1 (almost clear) on Day 1 of 
this study. 
o Randomized in a 1:1 ratio to receive a subcutaneous (SC) dose of 
imsidolimab 200 mg or placebo every 4 weeks starting on Day 1. 
1 
PROTOCOL SUMMARY 

Long-Term Safety and Efficacy of Imsidolimab in Subjects with GPP 
 
 
Clinical Study Protocol 
Protocol ANB019-302  
 
 
 
 
 
 
 
19 August 2022 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 
 
3 
 
• Partial responders: subjects who completed the Week 4 visit of the 
ANB019-301 study but do not have a GPPPGA score of 0 (clear) or 
1 (almost clear) on Day 1 of this study. 
o Will receive a SC dose of imsidolimab 200 mg every 4 weeks starting 
on Day 1. 
• Need for rescue therapy: Subjects who exited the ANB019-301 study 
starting at the Week 1 visit (after evaluation of primary endpoint) or later to 
receive rescue therapy in this study. 
o Subjects who received placebo in the ANB019-301 study and need 
rescue therapy will receive an intravenous (IV) dose of imsidolimab 
750 mg on Day 1, followed by a SC dose of imsidolimab 200 mg every 
4 weeks. 
o Subjects who received imsidolimab in the ANB019-301 study will be 
treated on Day 1 at the discretion of the Investigator with any available 
therapy (such as retinoids, cyclosporine, methotrexate, corticosteroids, 
or other appropriate therapy). 
Of note, the final treatment dose will be administered on Day 1009 
(Week 144). The treatment period ends at the Day 1037 (Week 148) visit and 
will be followed by a safety follow-up period. 
For scheduled onsite study visits, subjects will come to the study site to 
monitor safety and changes in disease activity on Day 1, Day 3 (applicable 
only for subjects receiving an IV dose on Day 1), Day 8 (Week 1) (applicable 
only for subjects receiving an IV dose on Day 1), Day 15 (Week 2), and 
Day 29 (Week 4), and then every 4 weeks during the treatment period. After 
Day 1037 (Week 148) visit (end of treatment [EOT]), subjects will enter the 
safety follow-up period and will be asked to come at Day 1065 (Week 152) 
and Day 1093 (Week 156 / end of study [EOS]) visits. Of note, subjects who 
were assigned to imsidolimab in the ANB019-301 study and receive other 
rescue therapy on Day 1 of this study will be asked to return for a final safety 
follow-up visit 12 weeks after receiving their study treatment dose in the 
ANB019-301 study. In this case, assessments described for the 
Day 1093 (Week 156) visit will be performed. In case of early termination 
(ET) during the study, subjects will be asked to come for an ET visit 12 weeks 
after their final study treatment dose. All procedures will be conducted in 
accordance with the Schedule of Activities (SoA) in Section 1.3. 
In case an IV dose is administered, subjects will be allowed to leave the study 
site beginning 2 hours after the end of IV administration (end of the infusion) 
and with the Investigator’s approval. In case of SC administration(s), subjects 
will be permitted to leave the study site 15 minutes after each SC 
administration and with the Investigator’s approval. 
Safety assessments will include adverse event (AE)/serious adverse event 
(SAE) monitoring, vital signs, physical examination, electrocardiograms 

Long-Term Safety and Efficacy of Imsidolimab in Subjects with GPP 
 
 
Clinical Study Protocol 
Protocol ANB019-302  
 
 
 
 
 
 
 
19 August 2022 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 
 
4 
 
(ECGs), and clinical laboratory tests (hematology, biochemistry, and 
urinalysis). 
Disease activity will be evaluated for all subjects using GPPPGA, Pustulation 
Rating Scale (PRS), modified Japanese Dermatology Association (mJDA) 
severity index, Clinical Global Impression (CGI), Clinician Global Impression 
of Change (CGI-C), Generalized Pustular Psoriasis Area and Severity Index 
(GPPASI), total body surface area (BSA) affected with GPP, BSA affected 
with pustules (excluding palms and soles), pain Numeric Rating Scale (NRS), 
Dermatology Life Quality Index (DLQI), Euro Quality of Life 5 Dimensions 
5 Levels (EQ-5D-5L), Patient Global Impression of Severity (PGI-S), Patient 
Global Impression of Bother (PGI-B), Patient Global Impression of Change 
(PGI-C), Subject Satisfaction Questionnaire (SSQ), Subject Satisfaction 
Rating Scale (SSRS), and Psoriasis Area Severity Index (PASI) (if concurrent 
plaque psoriasis is present on Day 1 of the ANB019-301 study). 
Blood samples to determine PK and immunogenicity (presence of anti-drug 
antibodies [ADA] to imsidolimab) will be collected on Day 1 before the 
administration of the study treatment and at other time points as specified in 
the SoA (Section 1.3). Optional blood samples for analysis of messenger 
ribonucleic acid (mRNA) expression will be collected at Day 169 (Week 24) 
visit. In addition, standardized photographs will be taken to document study 
outcome at the time points specified in the SoA. 
Objectives: 
Primary Objective: 
• To evaluate the long-term safety of imsidolimab in subjects with GPP who 
have participated in the ANB019-301 study 
Secondary Objective: 
• To evaluate the long-term efficacy of imsidolimab in subjects with GPP 
who have participated in the ANB019-301 study 
Exploratory Objectives: 
• To evaluate the PK of imsidolimab in subjects with GPP 
• To evaluate the immunogenicity of imsidolimab 
• To perform pharmacogenomic analysis 
• To evaluate the effect of imsidolimab on plaque psoriasis, for subjects with 
concurrent plaque psoriasis on Day 1 of the ANB019-301 study 
Endpoints: 
Safety Endpoints: 
• Incidence of AEs, SAEs, and AEs leading to withdrawals, as well as 
changes in vital signs, clinical laboratory parameters (hematology, 
biochemistry, and urinalysis), and 12-lead ECGs 

Long-Term Safety and Efficacy of Imsidolimab in Subjects with GPP 
 
 
Clinical Study Protocol 
Protocol ANB019-302  
 
 
 
 
 
 
 
19 August 2022 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 
 
5 
 
 
Secondary Efficacy Endpoints: 
• Proportion of subjects with zero recurrence of GPP flare (defined by a 
GPPPGA ≥ 3 [moderate] in subjects who had previously achieved a 
GPPPGA score of 0 [clear] or 1 [almost clear]) through Week 24 
• Proportion of subjects in remission (defined by a GPPPGA score of 
0 [clear] or 1 [almost clear]) at Week 24, without intake of any rescue 
medications during the treatment period 
• Time to first GPP flare recurrence 
• Proportion of subjects with a GPPPGA score of 0 (clear) or 1 (almost clear) 
at Week 24 
• Proportion of subjects with a PRS score of 0 (clear) or 1 (almost clear) at 
Week 24 
• Time to first pustulation flare recurrence (defined by a PRS ≥ 3 [moderate] 
in subjects who had previously achieved a PRS score of 0 [clear] or 
1 [almost clear]) 
• Proportion of subjects with a clinical response on the CGI scale at 
Week 24. Clinical response is defined as “Very much improved,” “Much 
improved,” and “Minimally improved” on CGI scale according to the 
mJDA severity index total score 
• Proportion of subjects losing clinical response on the CGI scale (defined as 
subjects who had previously achieved clinical response defined as 
“minimally improved” or better on CGI scale according to the mJDA 
severity index total score and worsen to either “no change” or “worsened” 
on the CGI scale) at Week 24 
• Change from Baseline in BSA affected with erythema with pustules as 
assessed by the mJDA severity index at Week 24 
• Percent change from Baseline in BSA affected with erythema with pustules 
as assessed by the mJDA severity index at Week 24 
• Change from Baseline in BSA affected with total erythema as assessed by 
the mJDA severity index at Week 24 
• Percent change from Baseline in BSA affected with total erythema as 
assessed by the mJDA severity index at Week 24 
Exploratory Efficacy Endpoints: 
• Proportion of subjects with zero recurrence of GPP flare (defined by a 
GPPPGA ≥ 3 [moderate] in subjects who had previously achieved a 
GPPPGA score of 0 [clear] or 1 [almost clear]) through Week 52, 
Week 104, Week 148, and Week 156 
• Proportion of subjects in remission (defined by a GPPPGA score of 
0 [clear] or 1 [almost clear]) at Week 52, Week 104, Week 148, and 
Week 156, without intake of any rescue medications during the treatment 
period 
• Proportion of subjects with a GPPPGA score of 0 (clear) or 1 (almost clear) 
at each visit except Week 24 

Long-Term Safety and Efficacy of Imsidolimab in Subjects with GPP 
 
 
Clinical Study Protocol 
Protocol ANB019-302  
 
 
 
 
 
 
 
19 August 2022 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 
 
6 
 
• Proportion of subjects with a PRS score of 0 (clear) or 1 (almost clear) at 
each visit except Week 24 
• Proportion of subjects with a clinical response on the CGI scale at each visit 
except Week 24. Clinical response is defined as “Very much improved,” 
“Much improved,” and “Minimally improved” on CGI scale according to 
the mJDA severity index total score 
• Proportion of subjects losing clinical response on the CGI scale (defined as 
subjects who had previously achieved clinical response defined as 
“minimally improved” or better on CGI scale according to the mJDA 
severity index total score and worsen to either “no change” or “worsened” 
on the CGI scale) at each visit except Week 24 
• Change from Baseline in BSA affected with erythema with pustules as 
assessed by the mJDA severity index at each visit except Week 24 
• Percent change from Baseline in BSA affected with erythema with pustules 
as assessed by the mJDA severity index at each visit except Week 24 
• Change from Baseline in BSA affected with total erythema as assessed by 
the mJDA severity index at each visit except Week 24 
• Percent change from Baseline in BSA affected with total erythema as 
assessed by the mJDA severity index at each visit except Week 24 
• Change from Baseline in BSA affected with edema as assessed by the 
mJDA severity index at each visit 
• Percent change from Baseline in BSA affected with edema as assessed by 
the mJDA severity index at each visit 
• Proportion of subjects with at least 3-point decrease from Baseline in pain 
NRS at each visit for subjects with a Baseline pain NRS of at least 3 
• Change from Baseline in GPPPGA score at each visit 
• Proportion of subjects with at least a 2-point decrease from Baseline in 
GPPPGA score at each visit 
• Time to loss of response (defined by a GPPPGA score of ≥ 2 [mild] in 
subjects who had previously achieved a GPPPGA score of 0 [clear] or 
1 [almost clear]) 
• Proportion of subjects with a maintenance of effect (defined by a GPPPGA 
score 0 [clear] or 1 [almost clear] at Week 24, Week 52, Week 104 and 
Week 148 in subjects who had previously achieved a GPPPGA score of 
0 [clear] or 1 [almost clear]) 
• Change from Baseline in PRS score at each visit 
• Proportion of subjects with at least a 2-point decrease from Baseline in 
PRS score at each visit 
• Change from Baseline in mJDA severity index total score (sum of skin 
lesion total score and systemic manifestation total score) at each visit 
• Change from Baseline in skin lesion total score (sum of erythema with 
pustules, total erythema, and edema scores) of the mJDA severity index at 
each visit 
• Change from Baseline in individual scores of erythema with pustules, total 
erythema, and edema of the mJDA severity index at each visit 

Long-Term Safety and Efficacy of Imsidolimab in Subjects with GPP 
 
 
Clinical Study Protocol 
Protocol ANB019-302  
 
 
 
 
 
 
 
19 August 2022 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 
 
7 
 
• Change from Baseline in total score of systemic manifestations and 
laboratory findings (sum of fever, white blood cell [WBC] count, 
C-reactive protein [CRP], serum albumin) of the mJDA severity index at 
each visit 
• Change from Baseline in individual scores of systemic manifestations and 
laboratory findings (fever, WBC count, CRP, serum albumin) of the mJDA 
severity index at each visit 
• Change from Baseline in absolute values of systemic manifestations and 
laboratory findings as assessed by the mJDA severity index at each visit 
• Percent change from Baseline in absolute values of systemic manifestations 
and laboratory findings as assessed by the mJDA severity index at each 
visit 
• Proportion of subjects in each response category for the CGI-C at each visit 
• Proportion of subjects achieving an improvement of 50% from Baseline in 
GPPASI (GPPASI 50) at each visit 
• Proportion of subjects achieving an improvement of 75% from Baseline in 
GPPASI (GPPASI 75) at each visit 
• Time to loss of 50% of GPPASI improvement from Baseline in subjects 
who achieved GPPASI 75 
• Change from Baseline in GPPPASI at each visit 
• Percent change from Baseline in GPPPASI at each visit 
• Change from Baseline in total BSA affected with GPP at each visit 
• Percent change from Baseline in total BSA affected with GPP at each visit 
• Change from Baseline in BSA (excluding palms and soles) affected with 
pustule at each visit 
• Percent change from Baseline in BSA (excluding palms and soles) affected 
with pustule at each visit 
• Change from Baseline in EQ-5D-5L at Week 12, Week 24, Week 52, 
Week 104, Week 148 and Week 156 
• Change from Baseline in DLQI at Week 12, Week 24, Week 52, 
Week 104, Week 148, and Week 156 
• Change from Baseline in pain NRS at each visit 
• Percent change from Baseline in pain NRS at each visit 
• Proportion of subjects with at least 4-point decrease from Baseline in pain 
NRS at each visit for subjects with a Baseline pain NRS of at least 4 
• Proportion of subjects in each response category for each question for the 
PGI-S at each visit 
• Proportion of subjects in each response category for the PGI-B at each visit 
• Proportion of subjects in each response category for the PGI-C at each visit 
• Proportion of subjects achieving a “None” or “Mild” for each question in 
the PGI-S at each visit 
• Proportion of subjects achieving “A little bothered” or “Not bothered at 
all” for the PGI-B at each visit 
• Proportion of subjects achieving “A little better,” “Better” or “Much 
better” for the PGI-C at each visit 

Long-Term Safety and Efficacy of Imsidolimab in Subjects with GPP 
 
 
Clinical Study Protocol 
Protocol ANB019-302  
 
 
 
 
 
 
 
19 August 2022 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 
 
8 
 
• Proportion of subjects in each response category for the SSQ at each visit 
• Proportion of subjects achieving “slightly satisfied”, “somewhat satisfied” 
or “extremely satisfied” for the SSQ at each visit 
• Proportion of subjects in each response category for the SSRS at Week 12, 
Week 24, Week 52, Week 104, Week 148 and Week 156 
• Proportion of subjects achieving “slightly satisfied”, “somewhat satisfied” 
or “extremely satisfied” for the SSRS at Week 12, Week 24, Week 52, 
Week 104, Week 148 and Week 156 
• Proportion of subjects receiving topical rescue medication from Week 16 to 
Week 24, Week 16 to Week 52, Week 16 to Week 104, Week 16 to 
Week 148, and Week 16 to Week 156 
Other Exploratory Endpoints: 
• Serum concentration of imsidolimab following administration to evaluate 
PK 
• Presence of ADA to imsidolimab 
• Optional blood genetic testing: mRNA 
• Change from Baseline in PASI (for subjects with concurrent plaque 
psoriasis on Day 1 of the ANB019-301 study) at each visit 
• Proportion of subjects achieving an improvement of 50% from Baseline in 
PASI (PASI 50) (for subjects with concurrent plaque psoriasis on Day 1 of 
the ANB019-301 study) at each visit 
• Proportion of subjects achieving an improvement of 75% from Baseline in 
PASI (PASI 75) (for subjects with concurrent plaque psoriasis on Day 1 of 
the ANB019-301 study) at each visit 
Study 
Population: 
Male and female subjects who participated in the ANB019-301 study will be 
allowed to enter in this study, if one of the following criteria is met: 
• If they completed at least the Week 1 visit of the ANB019-301 study 
without the use of rescue/prohibited medication for GPP and needed rescue 
medication starting at Week 1 or later during the ANB019-301 study; or 
• If they completed the Week 4 visit of the ANB019-301 study, and did not 
need or use rescue/prohibited medication for GPP during their entire 
participation in the ANB019-301 study. 
Phase: 
3 
Study Sites 
Enrolling 
Subjects: 
Up to 80 study sites located globally are expected to participate in this study. 
Description 
of Study 
Treatments: 
Imsidolimab will be provided in a glass vial as a sterile, colorless to yellow, 
and clear to slightly opalescent solution for either IV infusion or SC injection. 
The placebo contains no active ingredient and will be provided as a sterile, 
colorless to yellow, and clear to slightly opalescent solution for SC injection. 

Long-Term Safety and Efficacy of Imsidolimab in Subjects with GPP 
 
 
Clinical Study Protocol 
Protocol ANB019-302  
 
 
 
 
 
 
 
19 August 2022 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 
 
9 
 
Imsidolimab may be administered as follows: 
• IV dose of imsidolimab 750 mg (1-hour infusion duration) in polyvinyl 
chloride or polyolefin bags following dilution to a total volume of 100 mL 
with 0.9% sodium chloride; or 
• SC dose of imsidolimab 200 mg. 
Placebo may also be administered as SC dose in the same volume as 
imsidolimab. 
During the treatment period, eligible subjects will receive the treatment as 
described below depending on the study status on Day 1 (refer to Section 4.1 
for additional details on subject’s status and Section 6.1.2 for additional 
details on treatment administration): 
• Responders will be randomized in a 1:1 ratio to receive a SC dose of 
imsidolimab 200 mg or placebo every 4 weeks starting on Day 1; 
• Partial responders will receive a SC dose of imsidolimab 200 mg every 
4 weeks starting on Day 1; 
• Subjects who received placebo in the ANB019-301 study and need rescue 
therapy will receive an IV dose of imsidolimab 750 mg on Day 1, followed 
by a SC dose of imsidolimab 200 mg every 4 weeks; 
• Subjects who received imsidolimab in the ANB019-301 study and need 
rescue therapy will be treated on Day 1 at the discretion of the Investigator 
with any available therapy (such as retinoids, cyclosporine, methotrexate, 
corticosteroids, or other appropriate therapy). 
Rescue 
Medication: 
In case of flare (defined by GPPPGA ≥ 3 [moderate] in subjects who had 
previously achieved a GPPPGA score of 0 [clear] or 1 [almost clear]) after 
Day 1, the following treatments will be provided: 
• Subjects assigned to placebo in this study will receive an IV dose of 
imsidolimab 750 mg followed by a SC dose of imsidolimab 200 mg every 
4 weeks. 
• Subjects assigned to imsidolimab in this study will be treated at the 
discretion of the Investigator with any available therapy (such as retinoids, 
cyclosporine, methotrexate, corticosteroids, or other appropriate therapy). 
Subjects who experience a GPP flare between scheduled study visits may 
contact the study site to arrange an unscheduled visit. 
In addition, starting at Day 113 (Week 16), a subject who requires topical 
rescue medication, as judged by the Investigator and provided that he or she 
has a GPPPGA score of at least 3 (moderate severity), will be allowed to use 
topical rescue medications, such as corticosteroids, retinoid or vitamin A or D 
analog preparations, tacrolimus, calcineurin inhibitor, topical H1 and H2 
antihistamines, tar preparations, or topical antimicrobials). 
Additional details are provided in Table 2 and Section 6.5.3. 

Long-Term Safety and Efficacy of Imsidolimab in Subjects with GPP 
 
 
Clinical Study Protocol 
Protocol ANB019-302  
 
 
 
 
 
 
 
19 August 2022 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 
 
10 
 
 
Subject 
Duration: 
The maximum study duration per subject included in this study is 
approximately 156 weeks from first visit to last visit (including the treatment 
period and the safety follow-up period). However, subjects who were assigned 
to imsidolimab in the ANB019-301 study and receive other rescue therapy on 
Day 1 of this study will be asked to return for a final safety follow-up visit 
12 weeks after receiving their study treatment dose in the ANB019-301 study. 
In this case, assessments described for the Day 1093 (Week 156) visit will be 
performed. 
 
 
 
 
 

Long-Term Safety and Efficacy of Imsidolimab in Subjects with GPP 
 
 
Clinical Study Protocol 
Protocol ANB019-302  
 
 
 
 
 
 
 
19 August 2022 
Confidential and proprietary. Permission should be obtained before any reproduction.  
 
 
11 
1.2 
SCHEMA 
 
Figure 1: Study Schema 
 
 
 
Abbreviations: D, day; EOS, end of study; EOT, end of treatment; IV, intravenous; SC, subcutaneous; W, week. 
a The Day 1 visit of this study should ideally occur on the same day as the final study visit of the ANB019-301 study, in which case, subjects will enter this study 
directly after all assessments of the final ANB019-301 study visit are completed. Assessments that are common to both studies will be performed only once if the 
visits are on the same day. If scheduled on two separate days, the Day 1 visit of this study should occur no later than 1 week after completing the final study visit of 
the ANB019-301 study. No screening visit is required for this study. 
b Refer to Section 6.1.2 for specific visits were the study treatment needs to be administered and the treatment assignment depending on subject’s status on Day 1. 
c Subjects who were assigned to imsidolimab in the ANB019-301 study and receive other rescue therapy on Day 1 of this study will be asked to return for a final 
safety follow-up visit 12 weeks after receiving their study treatment dose in the ANB019-301 study. In this case, assessments described for the 
Day 1093 (Week 156) visit will be performed.